Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor
暂无分享,去创建一个
H. Alexander | G. Paciotti | L. Tamarkin | M. Puhlmann | J. Farma | P. Soriano | D. Cox | Perry A. Soriano
[1] A. Eggermont,et al. Addition of low-dose tumor necrosis factor-&agr; to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats , 2005, Anti-cancer drugs.
[2] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[3] A. Eggermont,et al. One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases , 2004, Annals of surgery.
[4] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[5] Rakesh K. Jain,et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.
[6] W. Fiers,et al. Tumor necrosis factor‐α augmented tumor response in B16BL6 melanoma‐bearing mice treated with stealth liposomal doxorubicin (Doxil®) correlates with altered Doxil® pharmacokinetics , 2004, International journal of cancer.
[7] Lawrence Tamarkin,et al. Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery , 2004, Drug delivery.
[8] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[9] S. Libutti,et al. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. , 2002, Blood.
[10] Dai Fukumura,et al. Dissecting tumour pathophysiology using intravital microscopy , 2002, Nature Reviews Cancer.
[11] A. Eggermont,et al. Low‐dose tumor necrosis factor‐α augments antitumor activity of stealth liposomal doxorubicin (DOXIL®) in soft tissue sarcoma‐bearing rats , 2000, International journal of cancer.
[12] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[13] A. Eggermont,et al. TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects , 2000, British Journal of Cancer.
[14] T. Scherstén,et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[15] C. Rüegg,et al. Clinical applications of TNF-α in cancer , 1998 .
[16] D. Fraker,et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Schlag,et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.
[18] A. Girbes,et al. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system. , 1996, Cancer research.
[19] R K Jain,et al. Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. , 1996, The American journal of pathology.
[20] J. Kirkwood,et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. , 1995, The cancer journal from Scientific American.
[21] G. Rosner,et al. Measurement of material extravasation in microvascular networks using fluorescence video-microscopy. , 1993, Microvascular research.
[22] R. Jain,et al. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. , 1993, Microvascular research.
[23] R. Jain,et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. , 1992, Cancer research.
[24] D. Stern,et al. Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.
[25] J. Bertram,et al. Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. , 1980, Cancer letters.
[26] T. Corbett,et al. A colon tumor model for anticancer agent evaluation , 1975, Cancer.
[27] R L Kassel,et al. An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[28] W. Molenaar,et al. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor , 2006, Annals of Surgical Oncology.
[29] Robert N. Hughes,et al. Cancer: Principles and Practice of Oncology , 2005 .
[30] P. Carmeliet,et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy , 2001, Nature Medicine.
[31] A. Eggermont,et al. Systemic Toxicity and Cytokine/Acute Phase Protein Levels in Patients After Isolated Limb Perfusion With Tumor Necrosis Factor-a Complicated by High Leakage , 2000, Annals of Surgical Oncology.
[32] S. Libutti,et al. National Cancer Institute Experience with Regional Therapy for Unresectable Primary and Metastatic Cancer of the Liver or Peritoneal Cavity , 2000 .
[33] S. Libutti,et al. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). , 1999, Cancer research.
[34] I. B. Borel Rinkes,et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[35] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .